謝興邦

HP Hsieh 2謝興邦  特聘研究員兼所長
生技與藥物研究所
Email: hphsieh@nhri.edu.tw
Podcast:藥物研發上的小問題大解惑 上集  下集
實驗室網頁:https://www.hphsiehlab.com/

 

學歷

  • 美國紐約州立大學石溪分校化學博士 (1993)
  • 國立清華大學化學碩士 (1987)
  • 國立清華大學化學學士 (1985)

經歷

  • 國家衛生研究院生技與藥物研究所 特聘研究員兼所長 (2023/1~)
  • 中央研究院生醫轉譯研究中心 合聘研究員 (2023/1~)
  • 國立清華大學化學系 合聘教授 (2014/8~)
  • 國立交通大學生物科技學系 合聘教授 (2017/8~)
  • 國家衛生研究院生技與藥物研究所 研究員 (2007/9~2022/12)
  • 嚴重特殊傳染性肺炎中央流行疫情指揮中心 研究發展組小組長 (2020/7~)
  • 中央研究院生醫轉譯研究中心 研究員兼副主任 (2020/1-2022/12)
  • 國家衛生研究院「藥物化學加值創新研發中心」 創辦主持人 (2018~2019)
  • 中國化學會 理事 常務理事(2017~2020)
  • 國家衛生研究院生技與藥物研究所 副所長 (2015/4~2019/12)
  • 國家衛生研究院技轉及育成中心 代理主任 (2018/9~2019/3)
  • 國家衛生研究院學術發展處 處長 (2012/2~2014/10)
  • 國家衛生研究院技轉及育成中心 主任 (2009/3~2012/2)
  • 國家衛生研究院圖書館 主任 (2007/11~2009/3)
  • 國家衛生研究院生物技術與藥物研究組 副研究員 (2003/2~2007/9)
  • 國立清華大學化學系 兼任教授 (2008~2014)
  • 國家衛生研究院生物技術與藥物研究組 助研究員 (1998/5~2003/2)
  • 中央研究院生物化學所 博士後研究員 (1996~1997)
  • 美國麻薩諸塞州波士頓學院 研究專員 (1994~1995)

研究興趣

新藥研發，藥物設計與合成，化學生物，天然物合成

研究成果

謝興邦教授實驗室主要是專注於從事抗癌、抗病毒及糖尿病等新藥研發工作。目前已發表125篇國際論文，其中有29篇發表在藥物化學領域頂尖期刊 — Journal of Medicinal Chemistry。此外亦取得62項國內外專利，並產出三項抗癌新穎候選藥物－『DBPR104』、『DBPR112』、『DBPR114』，其中『DBPR104』已在台灣完成臨床一期和二期臨床試驗；『DBPR112』目前正在台灣進行第一期臨床試驗；『DBPR114』於2017年7月和11月分別獲得美國和台灣IND(新藥臨床試驗)核准。已完成二項技術移轉分別給杏國新藥與安邦生技。

學術獎勵

  • 美國國家發明家學院院士(NAI Fellow) (2023)
  • 中國化學會化學技術獎章 (2022)
  • 國際生醫加速器合作計畫Pitch Day (第二名) (2019)
  • 科技部未來科技突破獎 (2018)
  • 科技部傑出研究獎 (2017)
  • 科技部未來科技突破獎 (2017)
  • 第26屆王民寧獎 (2016)
  • 國家衛生研究院傑出學術成就獎 (2015)
  • 國際傑出發明家終身成就獎(2014)
  • 第二十屆東元獎 (2013)
  • 第十屆國家新創獎(2013)
  • 國際傑出發明家學術國光獎章 (2012)
  • 董大成博士癌症基礎醫學研究傑出獎 (2011)
  • 國科會傑出研究獎 (2010)
  • 經濟部智慧財產局「國家發明創作獎」 (2010)
  • 永信李天德卓越醫藥科技獎 (2009)
  • 國家衛生研究院年輕學者學術成就獎 (2006)

論文發表(近十年內)

2023

  1. Li, M. C.; Coumar, M. ; Lin, . Y.; Lin, Y. S.; Huang, G. L.; Chen, C. H.; Lien, T. W.; Wu, Y. W.; Chen, Y. T.; Chen, C. P.; Huang, Y. C.; Yeh, K. C.; Yang, C. M.; Kalita, B.; Pan, S. L.; Hsu, T. A.; Yeh, T. K.; Chen, C. T.; Hsieh, H. P.* “Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung Cancer” Med. Chem. 2023, accepted (corresponding author) (SCI: 8.039)(3/63, CHEMISTRY, MEDICINAL)

2022

  1. Kumari, M.; Lu, R. M.; Li, M. C.; Huang, J. L.; Hsu, F. F.; Ko, S. H.; Ke, F. Y.; Su, S. C.; Liang, K. H.; Yuan, J. P. Y.; Chiang, H. L.; Sun, C. P.; Lee, I. J.; Li, W. S.; Hsieh, H. P.; Tao, M. H.; Wu, H. C.* “A Critical Overview of Current Progress for COVID‑19: Development of Vaccines, Antiviral Drugs, and Therapeutic Antibodies” Biomed. Sci. 2022, 29, Article number 68. (SCI: 12.771) (24/195, CELL BIOLOGY) Times Cited: 6
  2. Chen, C. M.*; Hsieh, H. P.* “Recent Advances in Total Synthesis of Natural Products by Masked Ortho-benzoquinones” Chin. Chem. Soc. 2022, 69, 1210-1222. (corresponding author) (SCI:1.753) (135/179, CHEMISTRY, MULTIDISCIPLINARY)
  3. Liu, J. S.; Fang, W. K.; Yang, S. M.; Wu, M. C.; Chen, T. J.; Chen, C. M.; Lin, T. Y.; Liu, K. L.; Wu, C. M.; Chen, Y. C.; Chuu, C. P.; Wang, L. Y.; Hsieh, H. P.; Kung, H. J.; Wang, W. C.* “Natural Product Myricetin is a Pan-KDM4 Inhibitor which with Poly Lactic-co-glycolic Acid Formulation Effectively Targets Castration-resistant Prostate Cancer” Biomed. Sci. 2022, 29, Article number 29. (SCI: 12.771) (24/195, CELL BIOLOGY) Times Cited: 1
  4. Lee, R. K.; Li, T. N.; Chang, S. Y.; Chao, T. L.; Kuo, C. H.; Pan, M. Y.; Chiou, Y. T.; Liao, K. J.; Yang, Y.; Wu, Y. H.; Huang, C. H.; Juan, H. F.; Hsieh, H. P.; Wang, L. H.* “Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2” J. Mol. Sci. 2022, 23, 4050. (SCI: 6.208) (50/179, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 7
  5. Lai, Y. L.; Wang, K. H.; Hsieh, H. P.; Yen, W. C.* “Novel FLT3/AURK Multikinase Inhibitor is Efficacious against Sorafenib-refractory and Sorafenib-resistant Hepatocellular Carcinoma” Biomed. Sci. 2022, 29, Article number 5. (SCI: 12.771) (24/195, CELL BIOLOGY)

2021

  1. Lee, K. H.; Yen, W. C.; Lin, W. H.; Wang, P. C.; Lai, Y. L.; Su, Y. C.; Chang, C. Y.; Wu, C. S.; Huang, Y. C.; Yang, C. M.; Chou, L. H.; Yeh, T. K.; Chen, C. T.; Shih, C.; Hsieh, H. P.* “Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model” Med. Chem. 2021, 64, 14477-14497. (corresponding author) (SCI: 8.039)(3/63, CHEMISTRY, MEDICINAL) Times Cited: 9
  2. Huang, C. Y.; Lin, S. Y.; Hsu, T. A.; Hsieh, H. P.*; Huang, M. H.* “Colloidal Assemblies Composed of Polymeric Micellar/Emulsified Systems Integrate Cancer Therapy Combining a Tumor- Associated Antigen Vaccine and Chemotherapeutic Regimens” Nanomaterials, 2021, 11, article 1844. (corresponding author) (SCI: 5.719)(55/179, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 1
  3. Li, M. C.; Lin, W. H.; Wang, P. C.; Su, Y. C.; Chen, P. Y.; Fan, C. M.; Chen, C. P.; Huang, C. L.; Chiu, C. H.; Chang, L.; Chen, C. T.; Yeh, T. K.; Hsieh, H. P.* “Design and Synthesis of Novel Orally Selective and Type II Pan-TRK Inhibitors to Overcome Mutations by Property-Driven Optimization” J. Med. Chem. 2021, 224, article 113673 (corresponding author) (SCI: 7.088) (5/63, CHEMISTRY, MEDICINAL) Times Cited: 8
  4. Charles, M. R. C.; Li, M. C.; Hsieh, H. P.*; Coumar, M. S.* “Mimicking H3 Substrate Arginine in the Design of G9a Lysine Methyltransferase Inhibitors for Cancer Therapy: A Computational Study for Structure-Based Drug Design” ACS Omega 2021, 6, 6100-6111. (corresponding author) (SCI: 4.132)(73/179, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 2
  5. Chen, Y. Y.; Zhang, Y. L.; Lee, G. H.; Tsou, L. K.; Zhang, M. M.; Hsieh, H. P.; Chen, J. J.; Ko, C. Y.; Wen, Z. H.; Sung P. J.* “Briarenols W-Z: Chlorine-Containing Polyoxygenated Briaranes from Octocoral Briareum Stechei (Kükenthal, 1908)” Drugs 2021, 19, 77. (SCI: 6.085)(10/63, CHEMISTRY, MEDICINAL) Times Cited: 3
  6. Huynh, T. H.; Lee, G. H.; Tanaka J.; Hsieh, H. P.; Tsou, L. K.; Zhang, M. M.; Kuo, T. J.; Wen, Z. H.; m Lu, C. K.; Sung P. J.* “Chlorinated briarane diterpenoids from octocoral Briareum stechei (Kükenthal, 1908)” Tetrahedron Lett. 2021, 69, 152976. (SCI: 2.032)(36/56, CHEMISTRY, ORGANIC) Times Cited: 1
  7. Taweesak, P.; Thongaram, P.; Kraikruan, P.; Thanetchaiyakup, A.; Chuanopparat, N.; Hsieh, H. P.; Uang, B. J.; Ngernmeesri, P.* “One-Pot Synthesis of Dibenzo[b,f]oxepines and Total Synthesis of Bauhinoxepin C” Org. Chem. 2021, 86, 1955-1963. (SCI: 4.198) (12/56, CHEMISTRY, ORGANIC) Times Cited: 4
  8. Reddy, J. S.; Chen, C. M.; Coumar, M. S.; Sun, H. Y.; Sun, N.; Hsieh, H. P.* “Development of a Robust Scale-up Synthetic Route for BPR1K871: A Clinical Candidate for the Treatment of Acute Myeloid Leukemia and Solid Tumors” Process Res. Dev. 2021, 25, 817-830. (corresponding author) (SCI: 3.858)(27/73, CHEMISTRY, ORGANIC) Times Cited: 2
  9. Syed, S. B.; Lin, S. Y.; Arya, H.; Fu, I. H.; Yeh, T. K.; Charles, M. R. C.; Periyasamy, L.; Hsieh, H. P.*; Coumar, M. S.* “Overcoming Vincristine Resistance in Cancer: Computational Design and Discovery of Piperine Inspired P-glycoprotein Inhibitors” Biol. Drug Des. 2021, 97, 51-66. (corresponding author) (SCI: 2.873)(43/63, CHEMISTRY, MEDICINAL) Times Cited: 3

2020

  1. Li, M. C.; Hsieh, H. P.* “Tumor-agnostic Inhibitors in Oncology: A New Phase for Precision Medicine” Chin. Chem. Soc. 2021, 67, 2216-2224. (corresponding author) (SCI: 1.753) (135/179, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 1
  2. Arya, H; Yadav, C. S.; Lin, S. Y.; Syed, S. B.; Charles, M. R. C.; Kannadasan, S.; Hsieh, H. P.; Singh, S. S.; Gajurel, P. R.; Coumar, M. S.* “Design of a Potent Anticancer Lead Inspired by Natural Products from Traditional Indian Medicine” Biomol. Struct. Dyn. 2020, 38, 3563-3577. (SCI: 5.235) (100/297, BIOCHEMISTRY & MOLECULAR BIOLOGY) Times Cited: 3
  3. Blay, V.*; Li, M. C.; Ho, S. P.; Stoller, M. L.; Hsieh, H. P.; Houston, D. R. “Design of Drug-like Hepsin Inhibitors against Prostate Cancer and Kidney Stones” Pharm. Sin B. 2020, 10, 1309-1320. (SCI: 14.907)(8/279, PHARMACOLOGY & PHARMACY) Times Cited: 4
  4. Lin, S. Y.; Chang, C. F.; Coumar, M. S.; Chen, P. Y.; Kuo, F. M.; Chen, C. H.; Li, M. C.; Lin, W. H.; Kuo, P. C.; Wang, S. Y.; Li, A. S.; Lin, C. Y.; Yang, C. M.; Yeh, T. K.; Song, J. S.; Hsu, J. T. A.; Hsieh, H. P.* “Drug-like Property Optimization: Discovery of Orally Bioavailable Quinazoline-Based Multi-Targeted Kinase Inhibitors” Bioorg Chem. 2020, 98, 103689. (corresponding author) (SCI: 5.307)(8/56, CHEMISTRY, ORGANIC) Times Cited: 6
  5. Lai, C. H.; Chen, R. Y.; Hsieh, H. P.; Tsai, S. J.; Chang, K. C.; Yen, C. J.; Huang, Y. C.; Liu, Y. W.; Lee, J. C.; Lai, Y. C.; Hung, L. Y.*; Lin, B. W.* “A Selective Aurora-A 5′-UTR siRNA Inhibits Tumor Growth and Metastasis” Cancer Lett. 2020, 472, 97-107. (SCI: 9.756)(35/245, ONCOLOGY) Times Cited: 10
  6. Charles, M. R. C.; Mahesh, A.; Lin, S. Y.;Hsieh, H. P.; Dhayalan, A.*; Coumar, M. S.* “Identification of Novel Quinoline Inhibitor for EHMT2/G9a through Virtual Screening” Biochimie. 2020, 168, 220-230. (SCI: 4.372)(140/297, BIOCHEMISTRY & MOLECULAR BIOLOGY) Times Cited: 8

2019

  1. Lin, S. Y.; Hsu Yung, C.; Peng, Y. H. ; Ke, Y. Y.; Lin, W. H.; Sun,H. Y.; Kuo, F. M.; Chen, P. Y.; Lien, T. W.; Chen, C. H.; Chu, C. Y.; Wang, S. Y.; Yeh, K. C.; Chen, C. P.; Hsu, J. TA; Wu, S. Y.; Yeh, T. K.; Chen, C. T.; Hsieh, H. P.* “Discovery of Clinical Candidate DBPR112, a Furanopyrimidine-based Epidermal Growth Factor Receptor Inhibitor for the Treatment of Non-Small Cell Lung Cancer” Med. Chem. 2019, 62, 10108-10123. (corresponding author) (SCI: 8.039)(3/63, CHEMISTRY, MEDICINAL) Times Cited: 11
  2. Tseng, P. H.; Sie, Z. L.; Liu, M. C.; Lin, H. S.; Yang, W. Y.; Lin, T. Y.; Hsieh, H. P.; Hung, S. C.; Cheng, C. L.; Wang, H. D.; Chang, H. H.*; Yuh, C. H.* “Identification of Two Novel Small Compounds that Inhibit Liver Cancer Formation in Zebrafish and Analysis of Their Conjugation to Nanodiamonds to Further Reduce Toxicity” Therapeutics 2019, 2, 1900105. (SCI: 5.003)(78/279,PHARMACOLOGY & PHARMACY) Times Cited: 7
  3. Lin, H. H.; Chen, S. J.; Shen, M. R.; Huang, Y. T.; Hsieh, H. P.; Lin, S. Y.; Lin, C. C.; Chang, W. W.; Chang, J. Y.* “Lysosomal Cysteine Protease Cathepsin S is Involved in Cancer Cell Motility by Regulating Store-Operated Ca2+ Entry” Biophys. Acta. Mol. Cell Res. 2019, 1866, 118517. (SCI: 5.011)(110/297, BIOCHEMISTRY & MOLECULAR BIOLOGY) Times Cited: 13
  4. Quattrini, L.; Coviello, V.; Sartini, S.; Di Desidero, T.; Orlandi, P.; Ke, Y. Y.; Liu, K. L.; Hsieh, H. P.; Bocci, G.; La Motta, C.* “Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation” Rep. 2019, 9, 9943. (SCI: 4.997)(19/74, MULTIDISCIPLINARY SCIENCES) Times Cited: 3
  5. Ramya, C. C. ; Hsieh, H. P.; Coumar, M. S.* “Delineating the Active Site Architecture of G9a Lysine Methyltransferase through Substrate and Inhibitor Binding Mode Analysis: A Molecular Dynamics Study” J. Biomol. Struct. Dyn. 2019, 37, 2581-2592. (SCI: 5.235) (100/297, BIOCHEMISTRY & MOLECULAR BIOLOGY) Times Cited: 9
  6. Charles, M. R. C.; Dhayalan, A.; Hsieh, H. P.; Coumar, M. S.* “Insights for the Design of Protein Lysine Methyltransferase G9a Inhibitors” Future Med. Chem. 2019, 11, 993-1014. (SCI: 4.767) (21/63, CHEMISTRY, MEDICINAL) Times Cited: 17

2018

  1. Chen, C. M.; Shiao, H. Y.; Uang, B. J.; Hsieh, H. P.* “Biomimetic Syntheses of (±)-Isopalhinine A, (±)-Palhinine A, and (±)-Palhinine D” Chem. Int. Ed. Engl. 2018, 57, 15572-15576. (corresponding author) (SCI: 16.823)(15/179, , CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 18 獲得德國蒂姆醫學出版社SYNFACTS主編蘇黎世聯邦理工學院Erick M. Carreira教授選為 “synfact of the month” 作專文介紹 (Synfacts, 2019, 15, 1)。榮獲第十五屆永信李天德醫藥科技獎之「傑出論文獎」。
  2. Ke, Y. Y.; Chang, C. P.; Lin, W. H.; Tsai, C. H.; Chiu, I. C.; Wang, W. P.; Wang, P. C.; Chen, P. Y.; Lin, W. H.; Chang, C. F.; Kuo, P. C.; Song, J. S.; Shih, C.; Hsieh, H. P.*; Chi, Y. H.* “Design and Synthesis of BPR1K653 Derivatives Targeting the Back Pocket of Aurora Kinases for Selective Isoform Inhibition” J. Med. Chem. 2018, 151, 533-545. (corresponding author) (SCI: 7.088)(5/63, CHEMISTRY, MEDICINAL) Times Cited: 8
  3. La Pietra, V.; Sartini, S.; Botta, L.; Antonelli, A.; Ferrari, S. M.; Fallahi, P.; Moriconi, A.; Coviello, V.; Quattrini, L.; Ke, Y. Y.; Hsieh, H. P.; Da Settimo, F.; Novellino, E.; La Motta, C.*; Marinelli, L.* “Challenging Clinically Unresponsive Medullary Thyroid Cancer: Discovery and Pharmacological Activity of Novel RET Inhibitors” J. Med. Chem. 2018, 150, 491-505. (SCI: 7.088)(5/63, CHEMISTRY, MEDICINAL) Times Cited: 10

2017

  1. Syed S. B.; Arya, H.; Fu, I. H.; Yeh, T. K.; Periyasamy, L.;Hsieh, H.P.*; Coumar, M. S.* “Targeting P-glycoprotein: Investigation of Piperine Analogs for Overcoming Drug Resistance in Cancer”. Rep. 2017, 7, 7972. (corresponding author) (SCI:4.997)(19/74, MULTIDISCIPLINARY SCIENCES) Times Cited: 65
  2. Singh, V. K.; Chang, H. H.; Kuo, C. C.; Shiao, H. Y.; Hsieh, H. P.; Coumar, M. S.* “Drug Repurposing for Chronic Myeloid Leukemia: In Silico and In Vitro Investigation of DrugBank Database for Allosteric Bcr-Abl Inhibitors” Biomol. Struct. Dyn. 2017, 35, 1833-1848. (SCI: 5.235) (100/297, BIOCHEMISTRY & MOLECULAR BIOLOGY) Times Cited: 18

2016

  1. Chang Hsu, Y.; Selvaraj, C. M. ; Wang, W. C.; Shiao, H. Y.; Ke, Y. Y.; Lin, W. H.; Kuo, C. C.; Chang, C. W.; Kuo, F. M.; Chen, P. Y.; Wang, S. Y.; Li, A. S.; Chen, C. H.; Kuo, P. C.; Chen, C. P.; Wu, M. H.; Huang, C. L.; Yen, K. J.; Chang, Y. I.; Hsu, J. T.; Chen, C. T.; Yeh, T. K.; Song, J. S.; Shih, C.; Hsieh, H. P.* “Discovery of BPR1K871, a Quinazoline Based, Multi-kinase Inhibitor for the Treatment of AML and Solid Tumors: Rational Design, Synthesis, In Vitro and In Vivo Evaluation” Oncotarget, 2016, 7, 86239-86256. (corresponding author) Times Cited: 12
  2. C. F.; Lin, W. H.; Ke, Y. Y.; Lin, Y. S.; Wang, W. C.; Chen, C. H.; Kuo, P. C.; Hsu, J. T.; Uang, B. J.*; Hsieh, H. P.* “Discovery of Novel Inhibitors of Aurora Kinases with Indazole Scaffold: In Silico Fragment-based and Knowledge-based Drug Design” Eur. J. Med. Chem. 2016, 124, 186-199. (corresponding author) (SCI: 7.088)(5/63, CHEMISTRY, MEDICINAL) Times Cited: 12
  3. Sarvagalla, S.; Hsieh, H. P.; Coumar, M. S.* “Therapeutic Polymeric Nanoparticles and the Methods of Making and Using thereof: A Patent Evaluation of WO2015036792” Expert Opin. Ther. Pat. 2016, 26, 751-755. (SCI: 6.714)(6/63, CHEMISTRY, MEDICINAL) Times Cited: 2
  4. Sarvagalla, S.; Cheung, C. H. A.; Tsai, J. Y.; Hsieh, H. P.; Coumar, M. S.* “Disruption of Protein-protein Interactions: Hot Spot Detection, Structure-based Virtual Screening and In Vitro Testing for the Anti-cancer Drug Target Survivin. RSC Advances 2016, 6, 31947-31959. (SCI: 4.036)(75/179, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 24

2015

  1. Ke, Y. Y.; Singh, V. K.; Coumar, M. S.; Hsu, Y. C.; Wang, W. C.; Song, J. S.; Chen, C. H.; Lin, W. H.; Wu, S. H.; Hsu, J. T.; Shih, C.; Hsieh H. P.* “Homology Modeling of DFG-in FMS-like Tyrosine Kinase 3 (FLT3) and Structure-based Virtual Screening for Inhibitor Identification” Rep. 2015, 5, 11702. (corresponding author) (SCI:4.997)(19/74, MULTIDISCIPLINARY SCIENCES) Times Cited: 52
  2. Wu, C. H.; Wang, C. J.; Chang, C. P.; Cheng, Y. C.; Song, J. S.; Jan, J. J.; Chou, M. C.; Ke, Y. Y.; Ma, J.; Wong, Y. C.; Hsieh, T. C.; Tien, Y. C.; Gullen, E. A.; Lo, C. F.; Cheng, C.Y.; Liu, Y. W.; Sadani, A. A.;Tsai, C. H.; Hsieh, H. P.; Tsou, L. K.*; Shia, K. S.* “Function-Oriented Development of CXCR4 Antagonists as Selective Human Immunodeficiency Virus (HIV)-1 Entry Inhibitors” Med. Chem. 2015, 58, 1452-1465. (SCI: 8.039)(3/63, CHEMISTRY, MEDICINAL) Times Cited: 23
  3. Sarvagalla, S.; Singh, V. K.; Ke, Y. Y.; Shiao, H. Y.; Lin, W. H.; Hsieh, H. P.; Hsu, J. T.; Coumar, M. S.* “Identification of Ligand Efficient, Fragment-like Hits from an HTS Library: Structure-based Virtual Screening and Docking Investigations of 2H– and 3H-Pyrazolo Tautomers for Aurora Kinase A Selectivity” Comput. Aided Mol. Design 2015, 29, 89-100. (SCI: 4.179)(21/72, BIOPHYSICS) Times Cited: 36

2014

  1. Velu, A. B.; Chen, G. W.; Hsieh, P. T.; Horng, J. T.; Hsu, J. T.; Hsieh, H. P.; Chen, T. C.; Weng, K. F. Shih, S. R.* “BPR-3P0128 Inhibits RNA-dependent RNA Polymerase Elongation and VPg Uridylylation Activities of Enterovirus 71.” Antiviral Res. 2014, 112, 18-25. (SCI: 10.103)(6/37, VIROLOGY) Times Cited: 16
  2. Lee, C. C.; Shiao, H. Y.; Wang, W. C.; Hsieh, H. P.* “Small-molecule EGFR Tyrosine Kinase Inhibitors for the Treatment of Cancer” Opin. Investig. Drugs. 2014, 23, 1333-1348. (corresponding author) (SCI: 6.498)(41/279, PHARMACOLOGY & PHARMACY) Times Cited: 44
  3. Chen, Y. P.; Lin, H. J.; Chen, J. S.; Tsai, M. Y.; Hsieh, H. P.; Chang, J. Y.; Chen, N. F.; Chang, K. C.; Huang, W. T.; Su, W. C.; Yang, S. T.; Chang, W. C.; Hung, L. Y.*; Chen, T. Y.* “CDKN1A-mediated Responsiveness of MLL-AF4-positive Acute Lymphoblastic Leukemia to Aurora Kinase-A Inhibitors” J. Cancer 2014, 135, 751-762. (SCI: 7.316)(52/245, ONCOLOGY) Times Cited: 6
  4. Ke, Y. Y.; Coumar, M. S.; Shiao, H. Y.; Wang, W. C.; Chen, C. W.; Song, J. S.; Chen, C. H.; Lin, W. H.; Wu, S. H.; Hsu, J. T.; Chang, C. M.; Hsieh, H. P.* “Ligand Efficiency Based Approach for Efficient Virtual Screening of Compound Libraries” J. Med. Chem. 2014, 83, 226-235. (corresponding author) (SCI: 7.088)(5/63, CHEMISTRY, MEDICINAL) Times Cited: 11
  5. Wang, W.C.; Shiao, H. Y.; Lee, C. C.; Fung, K. S.; Hsieh, H. P.* “Anaplastic Lymphoma Kinase (ALK) Inhibitors: A Review of Design and Discovery” MedChemComm. 2014, 5, 1266–1279. (corresponding author) (SCI: 5.121)(18/63, CHEMISTRY, MEDICINAL) Times Cited: 20
  6. Chang Hsu, Y.; Ke, Y. Y.; Shiao, H. Y.*; Lee, C. C.; Lin, W. H.; Chen, C. H.; Yen, K. J.; Hsu, J. T.; Chang, C.; Hsieh, H. P.* “Facile Identification of Dual FLT3-Aurora A Inhibitors: A Computer-Guided Drug Design Approach” ChemMedChem, 2014, 5, 953-961. (Selected as the Front Cover) (corresponding author) (SCI: 3.540)(34/63, CHEMISTRY, MEDICINAL) Times Cited: 25

2013

  1. Hou, C.C.; Tsai, T. L.; Su, W. P.; Hsieh, H. P.; Yeh, C. S.; Shieh, D. B.; Su, W. C. “Pronounced Induction of Endoplasmic Reticulum Stress and Tumor Suppression by Surfactant-free Poly(lactic-co-glycolic acid) Nanoparticles via Modulation of the PI3K Signaling Pathway” J. Nanomedicine. 2013, 8, 2689–2707. (SCI: 6.4)(28/276, PHARMACOLOGY & PHARMACY) Times Cited: 10
  2. Shiao, H. Y.; Coumar, M. S.; Chang, C. W.; Ke, Y. Y.; Chi, Y. H.; Chu, C. Y.; Sun, H. Y.; Chen, C. H.; Lin, W. H.; Fung, K. S.; Kuo, P. C.; Huang, C. T.; Chang, K. Y.; Lu, C. T.; Hsu, J. T.; Chen, C. T.; Jiang, W. T.; Chao, Y. S.; Hsieh, H. P.* “Optimization of Ligand and Lipophilic Efficiency To Identify an in Vivo Active Furano-Pyrimidine Aurora Kinase Inhibitor” Med. Chem. 2013, 56, 5247–5260. (NSC-101-2113-M-400-002-MY4) (corresponding author) (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 36
  3. Wang, X.; Wu, E.; Wu, J.; Wang, T. L.; Hsieh, H. P.; Liu, X.* “An Antimitotic and Antivascular Agent BPR0L075 Overcomes Multidrug Resistance and Induces Mitotic Catastrophe in Paclitaxel-Resistant Ovarian Cancer Cells” PLoS One. 2013, 8, e65686. (SCI: 3.24)(26/72, MULTIDISCIPLINARY SCIENCES) Times Cited: 21
  4. Wu, J. M.; Chen, C. T.; Coumar, M. S.; Lin, W. H.; Chen, Z. J.; Hsu, J. T.; Peng, Y. H.; Shiao, H. Y.; Lin, W. H.; Chu, C. Y.; Wu, J. S.; Lin, C. T.; Chen, C. P.; Hsueh, C. C.; Chang, K. Y.; Kao, L. P.; Huang, C. Y.; Chao, Y. S.; Wu, S. Y.*; Hsieh, H. P.*; Chi, Y. H.* “Aurora kinase inhibitors reveal mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules” Natl. Acad. Sci. U. S. A. 2013, 110, E1779-1787. (NSC-101-2113-M-400-002-MY4) (corresponding author) (SCI: 11.205)(8/72, MULTIDISCIPLINARY SCIENCES) Times Cited: 34
  5. Peng, Y. H.; Shiao, H. Y.; Tu, C. H.; Liu, P. M.; Hsu, J. T.; Amancha, P. K.; Wu, J. S.; Coumar, M. S.; Chen, C. H.; Wang, S. Y.; Lin, W. H.; Sun, H. Y.; Chao, Y. S.; Lyu, P. C.; Hsieh, H. P.*; Wu, S. Y.* “Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors” Med. Chem. 2013, 56, 3889-3903. (NSC-101-2113-M-400-002-MY4) (corresponding author) (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 76
  6. Shionome, Y.; Lin, W. H.; Shiao H. Y.; Hsieh H. P.; Hsu J. T.; Ouchi, T.* “A Novel Aurora-A Inhibitor, BPR1K0609S1, Sensitizes Colorectal Tumor Cells to 5-Fluorofracil (5-FU) treatment” J. Biol. Sci. 2013, 9, 403-411. (SCI: 6.582)(57/295, BIOCHEMISTRY & MOLECULAR BIOLOGY) Times Cited: 10
  7. Hsu, K. C.; Hung, H. C.; Horng, J. T.; Fang, M. Y.; Chang, C. Y.; Li, L. T.; Chen, Y. C.; Chou, D. L.; Chang, C. W.; Hsieh, H. P.; Yang, J. M.; Hsu, J. T.* “Parallel Screening of Wild-type and Drug-resistant Targets for Anti-resistance Neuraminidase Inhibitors” PLoS One. 2013, 8, e56704. (SCI: 3.24)(26/72, MULTIDISCIPLINARY SCIENCES) Times Cited: 9
  8. Ke, Y. Y.; Shiao, H. Y.; Hsu, Y. C.; Chu, C. Y.; Wang, W. C.; Lee, Y. C.; Lin, W. H.; Chen, C. H.; Hsu, J. T.; Chang, C. W.; Lin, C. W.; Yeh, T. K.; Chao, Y. S.; Coumar, M. S.*; Hsieh, H. P.* “3D-QSAR-Assisted Drug Design: Identification of a Potent Quinazoline-Based Aurora Kinase Inhibitor” ChemMedChem. 2013, 8, 136-148. (corresponding author) (SCI:3.466)(32/62, CHEMISTRY, MEDICINAL) Times Cited: 25
  9. Hsieh, H. P.; Chen, A. C.; Villarante, N. R.; Chuang, G. J.*; Liao, C. C.* “Substituent Effects on the Photorearrangements of Unsymmetrically Substituted Diazinobarrelenes” RSC Adv., 2013, 3, 1165-1178. (SCI: 3.361)(81/178, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 3

2012

  1. Shiao, H. Y.*; Kuo, C. C.; Horng, J. T.; Shih, S. R.; Chang, S. Y.; Liao, C. C.; Hsu, J. T.; Amancha, P. K.; Chao, Y. S.; Hsieh, H. P.* “An Efficient, Mild and Scalable Synthesis of Bioactive Compounds Containing the Angelicin Scaffold” Chin. Chem. Soc. 2012 59, 1548-1554. (Selected as the Front Cover) (NSC-98-2119-M-400-001-MY3) (corresponding author) (SCI:1.967)(119/178, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 5
  2. Yeh, J. Y.; Coumar, M. S.; Shiao, H. Y.; Lin, T. J.; Lee, Y. C.; Hung, H. C.; Ko, S.; Kuo, F. M.; Fang, M. Y.; Huang, Y. L.; Hsu, J. T.; Yeh, T. K.; Shih, S. R.; Chao, Y. S.; Horng, J. T.*; Hsieh, H. P.* “Anti-influenza Drug Discovery: Identification of an Orally Bioavailable Quinoline Derivative through Activity- and Property-Guided Lead Optimization” 2012, 9, 1546-1550. (corresponding author) (SCI:3.466) (32/62, CHEMISTRY, MEDICINAL) Times Cited: 5
  3. Liu, L.; Beck, H.; Wang, X.; Hsieh, H. P.; Mason, R. P.; Liu, X.* “Tubulin-Destabilizing Agent BPR0L075 Induces Vascular-Disruption in Human Breast Cancer Mammary Fat Pad Xenografts” PLoS One 2012, 7, e43314. (SCI: 3.24)(26/72, MULTIDISCIPLINARY SCIENCES) Times Cited: 23
  4. Hsu, J. T.; Yeh, J. Y.; Lin, T. J.; Li, M. L.; Wu, M. S.; Hsieh, C. F.; Chou, Y. C.; Tang, W. F.; Lau, K. S.; Hung, H. C.; Fang, M. Y.; Ko, S.; Hsieh, H. P.*; Horng, J. T.* “Identification of BPR3P0128 as an Inhibitor of Cap-Snatching Activities of Influenza Virus” Agents Chemother. 2012 56, 647-657. (corresponding author) (SCI: 5.191)(57/276, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY) Times Cited: 40
  5. Shiao, H. Y.*; Chiang, N. J.; Hsieh, H. P.* “Anaplastic Lymphoma Kinase (ALK) Inhibitors: New Cancer Breakthroughs for Lung Cancer ” Cancer Res. Pract. 2012, 27, 143-156. (corresponding author) (awardee invited article)
  6. Lin, W. H.; Song, J. S.; Lien, T. W.; Chang, C. Y.; Wu, S. H.; Huang, Y. W.; Chang, T. Y.; Fang, M. Y.; Yen, K. J.; Chen, C. H.; Chu, C. Y.; Hsieh, H. P.; Chen, Y. R.; Chao, Y. S.; Hsu, J. T.* “A High-throughput Cell-based Screening for L858R/T790M Mutant Epidermal Growth Factor Receptor Inhibitors ” Anticancer Res. 2012, 32, 147-151. (SCI: 2.48)(210/242, ONCOLOGY) Times Cited: 3

 專利申請與獲證

  1. Tsou, L. K.; Niu, G. H.; Hsieh, H. P.; Zhang, M.; Wen Z. H.; Sung, P. J. “Briarane Compounds and Their Use “, US Provision 63/428,303, Nov. 28, 2022.
  2. Hsieh, H. P.; Yen, W. C.; Wu, S. Y.; Li, M. C.; Lin, W. H.; Ke, Y. Y. “Inhibitors of TAM Receptors “, US Provision 63/399,404, Aug. 19, 2022.
  3. Hsieh, H. P.; Lee, K. H.; Lin, W. H.; Shih, C. “以雜環化合物作為激酶抑制劑的治療用途”, TW I757722, Mar. 11, 2022-April 10, 2040.
  4. Hsieh, H. P.; Lee, K. H.; Lin, W. H.; Shih, C. “Heterocyclic Compounds as Kinase Inhibitors for Therapeutic Uses​”, WO/2019/223632, April 9, 2020.
  5. Hsieh, H. P.; Coumar, M. S.; Chao, Y. S. “Fused Multicyclic Compounds as Protein Kinase Inhibitors”, KR1718386B1, March 21, 2017-Sep. 22, 2029.
  6. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Lin, W. H; Chen, Y. R.; Chao, Y. S. “Fused Bicyclic and Tricyclic Pyrimidine Compounds as EGFR Kinase Inhibitors”, KR1703941B1, 7, 2017- -Nov. 9, 2029.
  7. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors”, IN279196B, Jan. 20, 2017-April 22, 2029.
  8. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors”, EP2276346B1, Nov. 23, 2016-April 22, 2029.
  9. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors”, KR1667822B1, Oct. 19, 2016-April 22, 2029.
  10. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors”, CA2722220C, June 7,2016-April 22, 2029.
  11. Hsieh, H. P.; Coumar, M. S.; Chao, Y. S. “做為蛋白質激酶抑制劑之稠合多環化合物”, 0, March 23, 2016-Sep. 22, 2029.
  12. Lin, C. C.; Chang, WHW; Uang, B. J.; Chang, J. Y.; Chen, J. C.; Hsieh, H. P. “組織蛋白酶Ｓ抑制劑”, TWI516479, Jan 11, 2016-Dec. 6, 2030.
  13. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors”, AU2009241469, Aug. 20,2015-April 22, 2029.
  14. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Lin, W. H; Chen, Y. R.; Chao, Y. S. “Fused Bicyclic and Tricyclic Pyrimidine Compounds as EGFR Kinase Inhibitors”, JP5781934, July 24, 2015-Nov. 9, 2029.
  15. Hsieh, H. P.; Coumar, M. S.; Chao, Y. S. “Fused Multicyclic Compounds as Protein Kinase Inhibitors”, US9006252, April 14, 2015-Mar. 24, 2032.
  16. Lin, C. C.; Chang, WHW; Uang, B. J.; Chang, J. Y.; Chen, J. C.; Hsieh, H. P. “Cathepsin S inhibitors”, US8895497, Nov. 25, 2014-Dec. 6, 2030.
  17. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “作為極光激酶抑制劑的稠合雙環嘧啶化合物”, 4, Oct. 29,2014-April 22, 2029.
  18. Hsieh, H. P.; Yeh, J. Y.; Hsu, T. A.; Shih, S. R.; Horng, J. T.; Chang S. Y.; Chao, Y. S. “化合物於製造治療病毒感染的藥物之用途”, TWI457121, Oct. 21, 2014-June 11, 2029.
  19. Hsieh, H. P.; Yeh, J. Y.; Hsu, T. A.; Chao, Y. S. “Quinoline Compounds and their Use for Treating Viral Infection”, US8710079, April 29, 2014-April 21, 2031.
  20. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors”, JP5502072, March 20, 2014-April 22, 2029.
  21. Hsieh, H. P.; Chang, J. Y.; Kuo, C. C.; Chao, Y. S. “治療癌症的醫藥組成物”, TWI415852, Nov. 21, 2013-June 11, 2029.
  22. Hsieh, H. P.; Yeh, J. Y.; Hsu, T. A.; Chao, Y. S. “喹啉化合物及其用以治療病毒性感染之用途”, TWI410245, Oct. 1, 2013-April 22, 2031.
  23. Hsieh, H. P.; Coumar, M. S.; Chao, Y. S. “Fused Multicyclic Compounds as Protein Kinase Inhibitors”, EP2331530, Aug. 21, 2013-Sep. 22, 2029.
  24. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Lin, W. H; Chen, Y. R.; Chao, Y. S. “Fused Bicyclic and Tricyclic Pyrimidine Compounds as EGFR Kinase Inhibitors”, US8507502, Aug. 13, 2013– 9, 2029.
  25. Hsieh, H. P.; Coumar, M. S.; Chao, Y. S. “做為蛋白質激酶抑制劑之稠合多環化合物”, TWI400242, July 1, 2013-Sep. 23, 2029.
  26. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Lin, W. H; Chen, Y. R.; Chao, Y. S. “作為酪胺酸激酶抑制劑之稠合雙環及多環嘧啶化合物”, TWI385174, Feb. 11, 2013-Nov. 9, 2029.
  27. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “作為極光激酶抑制劑之稠合雙環嘧啶化合物”, TWI363627, May 11, 2012-April 29, 2029.
  28. Jiaang, W. T; Chao, Y. S.; Hsieh, H. P. “吡咯啉啶化合物”, TWI362388, April 21, 2012-Aug. 25, 2026.
  29. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors”, US8138194, March 20, 2012-April 22, 2029.
  30. Hsieh, H. P.; Liou, J. P.; Chang, J. Y.; Chang, C. W. “Indole Compounds”, CA2437104, March 6, 2012-Aug 13, 2023.
  31. Hsieh, H. P.; Hsu, T. A.; Chao, Y. S.; Chou, Y. C.; Wang, S. T. “引藻萃取物” , TWI356705, Jan. 21, 2012-Oct. 1, 2028.
  32. Jiaang, W. T; Chen, X.; Wu, S. Y.; Chao, Y. S.; Hsieh, H. P.; “Pyrrolidine Compounds”, CA2559611, Jan. 17, 2012-Mar 9, 2025.
  33. Hsieh, H. P.; Chang, J. Y.; Kuo, C. C.; Chao, Y. S. “Coumarin Compounds and Their Use for Treating Cancer”, US8058427, November 15, 2011-June 10, 2029.
  34. Hsieh, H. P.; Hsu, T. A.; Chao, Y. S.; Chou, Y. C.; Wang, S. T. “Extracts from Chlorella” US8048426, Nov. 1, 2011-April 30, 2029.
  35. Hsieh, H. P.; Hsu, T. A.; Hwang, D. R. “抑制Ｃ型肝炎病毒感染之倍半帖內酯類化合物及其醫藥組成物”, TWI344959, July 11, 2011-April 1, 2024.
  36. Hsu, T. A.; Hsieh, H. P.; Chao, Y. S.; Chen, C. M.; Jan, J. T.; Liu, H. W., “抑制冠狀病毒之醫藥組合物”, TWI343808, June 21, 2011-May 28, 2024.
  37. Hsu, T. A.; Hsieh, H. P.; Chao, Y. S.; Chen, C. M.; Jan, J. T.; Liu, H. W., “抑制冠狀病毒之醫藥組合物”, TWI343809, June 21, 2011-May 28, 2024.
  38. Hsu, T. A.; Hsieh, H. P.; Chao, Y. S.; Chen, C. M.; Jan, J. T.; Liu, H. W., “抑制冠狀病毒之醫藥組合物”, TWI343810, June 21, 2011-May 28, 2024.
  39. Hsieh, H. P.; Liou, J. P.; Chang, J. Y.; Chang, C. W. “Indole Compounds as Inhibitors of Tubulin Polymerisation for the Treatment of Angiogenesis-related Disorders”, EP1506960, April. 6, 2011-Aug. 7, 2023.
  40. Hsieh, H. P; Mahindroo, N.; Hsu, T. A.; Huang, C. F.; Chen, X.; Chao, Y. S. “吲哚化合物”, 8, December 1, 2010 – December 11, 2024.
  41. Hsieh, H. P.; Tung, Y. S.; Liou, J. P.; Chang, J. Y.; Chao, Y. S. “Anti-Tumor Compounds”, 7, December 1, 2010 – December 15, 2025.
  42. Jiaang, W. T; Chen, X.; Wu, S. Y.; Chao, Y. S.; Hsieh, H. P.; “Pyrrolidine Compounds”, CN1942186, Oct. 06, 2010-Mar 9, 2025.
  43. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “Indoline-sulfonamides compounds”, CA2598788, Aug. 3, 2010-Aug. 27, 2027.
  44. Hsieh, H. P.; Hsu, T. A.; Chao, Y. S.; Chou, Y. C.; Wang, S. T. “Extracts from Chlorella”, Singapore, 152154, July 15, 2010-Oct. 8, 2028.
  45. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “Indoline-sulfonamides compounds”, US7741495, June 22, 2010 – August 31, 2027.
  46. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “Indoline-sulfonamides compounds”, 日本特許第4521428號, May 28, 2010 – August 31, 2027.
  47. Jiaang, W. T; Chen, X.; Wu, S. Y.; Chao, Y. S.; Hsieh, H. P.; “Pyrrolidine Compounds”, US7687504, Mar. 30, 2010-Mar 9, 2025.
  48. Hsieh, H. P.; Liou, J. P.; Chang, J. Y.; Chang, C. W. “Indole Compounds”, US7632955, December 15, 2009 – December 12, 2022.
  49. Hsieh, H. P.; Liou, J. P.; Chang, J. Y.; Chang, C. W. “芳香羰吲哚化合物”, TWI317634, December 1, 2009 – December 11, 2022.
  50. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “吲哚啉磺胺化合物”, TWI315304, October 1, 2009 – August 31, 2027.
  51. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “Indoline-sulfonamides compounds”, KR10-0916989, September 4, 2009 – August 31, 2027.
  52. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “Indoline-sulfonamides compounds”, AU2007214336, June 4, 2009 – August 31, 2027.
  53. Hsu, T. A.; Hsieh, H. P.; Chao, Y. S.; Chen, C. M.; Jan, J. T.; Liu, H. W. “Treatment of Coronavirus Infection”, US7544712, June 9, 2009 – May 28, 2024.
  54. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “Indoline-sulfonamides compounds”, GB2441396, May 13, 2009 – August 31, 2027.
  55. Hsieh, H. P.; Liou, J. P.; Chang, J. Y.; Chang, C. W. “Indole Compounds,” US7528165, May 5, 2009 – December 12, 2022.
  56. Hsieh, H. P; Mahindroo, N.; Hsu, T. A.; Huang, C. F.; Chen, X.; Chao, Y. S. “吲哚化合物”, TWI304066, December 12, 2008 – December 11, 2024.
  57. Hsieh, H. P.; Tung, Y. S.; Liou, J. P.; Chang, J. Y.; Chao, Y. S. “Anti-Tumor Compounds,” US7456289, November 25, 2008 – December 15, 2025.
  58. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “Indoline-sulfonamides compounds”, NZ561060, November 13, 2008 – August 31, 2027.
  59. Hsieh, H. P; Mahindroo, N.; Hsu, T. A.; Huang, C. F.; Chen, X.; Chao, Y. S. “Indole Compounds” , US7449478, November 11, 2008 – December 3, 2024.
  60. Jiaang, W. T; Chao, Y. S.; Hsieh, H. P. “Pyrrolidine Compounds”, US7425633, September 16, 2008 – August 28, 2026.
  61. Jiaang, W. T; Chen, X.; Wu, S. Y.; Chao, Y. S.; Hsieh, H. P. “咯啶化合物”, TWI299039, July 21, 2008 – March 9, 2025.
  62. Hsieh, H. P.; Tung, Y. S.; Liou, J. P. Chang, J. Y.; Chao, Y. S. “抗腫瘤化合物”, TWI296195, May 1, 2008 – December 27, 2025.
  63. Jiaang, W. T; Chen, X.; Wu, S. Y.; Hsieh, H. P.; Chao, Y. S. “Pyrrolidine Compounds”, KR7038951, April 12, 2008 – August 28, 2
  64. Hsu, T. A.; Hsieh, H. P.; Juan, L. J; Chang, S. Y.; Kuo, Y. H. “一種抗病毒之醫藥組成物”, TW I293248, February 11, 2008 – May 21, 2023.
  65. Hsieh, H. P.; Liou, J. P.; Chang, J. Y.; Chang, C. W. “Indole Compounds”, US6933316, August 23, 2005 – December 12, 2022.
  66. Burrows, C. J.; Hsieh, H. P. “Steroidal Polyamines”, US5610149, 1997.

Comments are closed.